Peribronchiolar fibrosis is a prominent feature of airway remodeling in asthma and involves fibroblast growth and collagen deposition. Interleukin-13 (IL-13), a T-helper 2 cytokine, is a key mediator of airway remodeling in asthma, yet the mechanism through which IL-13 promotes fibroblast growth has not been investigated. In this study, we show that IL-13 stimulates the mitogenesis of mouse, rat, and human lung fibroblasts through release of a soluble mitogen that we identified as PDGF-AA. The IL-13-induced growth of human lung fibroblasts was attenuated by an anti-PDGF-AA neutralizing antibody, and IL-13 stimulated human lung fibroblasts to secrete PDGF-AA. Fibroblasts derived from mouse embryos possessing the lethal Patch mutation, which lack the PDGF-Rα, showed no mitogenic response to IL-13. However, Patch cells did exhibit IL-13-induced STAT-6 phosphorylation. Stable transfection of the PDGF-Rα into Patch cells restored the growth response to PDGF-AA and IL-13. Through the use of lung fibroblasts from STAT-6-deficient mice, we showed that IL-13-induced PDGF-AA release is STAT-6 dependent, but PDGF-AA-induced growth is STAT-6 independent. Finally, we showed that IL-1β enhanced IL-13-induced mitogenesis of rat lung fibroblasts through up-regulation of the PDGF-Rα. Our findings indicate that IL-13 acts in synergy with IL-1β to stimulate growth by coordinately up-regulating PDGF-AA and the PDGF-Rα, respectively.
IL-13, in particular, has been shown to be an essential mediator of allergen-induced Th2 immune responses in the lung leading to a variety of proinflammatory effects (2, 4) . Recent reports provide evidence that expression of IL-13 is increased in pulmonary cells and bronchoalveolar lavage (BAL) fluid from fibrotic human subjects (5) . Also, directed overexpression of IL-13 in the lung results in transgenic mice exhibiting significantly increased airway fibrosis compared with wild-type littermates (6) . Inhibition of IL-13 expression in transgenic mice reduces allergen-induced collagen deposition and airway hyperresponsiveness (2, 7, 8) . Both IL-13 and IL-4 activate the STAT-6 signaling pathway in human lung fibroblasts (9) . Numerous studies have shown that IL-13-mediated airway fibrosis and hyperresponsiveness are dependent on STAT-6 signaling, as transgenic mice deficient in STAT-6 are protected from these allergeninduced effects compared with wild-type mice (10) (11) (12) . Recently, IL-13 was reported to upregulate expression of TGF-β1, which is the major inducer of collagen expression by myofibroblasts (13) . Based on these observations, IL-13 appears to be a key contributor to airway inflammation and remodeling. Still, the mechanism by which IL-13 induces airway fibrosis has not been fully elucidated.
Surprisingly, relatively little is known regarding the effect of IL-13 on myofibroblast proliferation, a central feature of airway fibrosis. Kraft et al. (14) reported that IL-13 stimulates fibroblast proliferation in human subjects with mild asthma. In the present study, we demonstrate that IL-13 stimulates proliferation of lung fibroblasts in vitro by stimulating the autocrine release of platelet-derived growth factor (PDGF-AA). IL-13-induced PDGF-AA secretion was STAT-6 dependent, whereas PDGF-AA-induced mitogenesis was STAT-6 independent. Moreover, IL-1β synergistically enhanced IL-13-induced mitogenesis in rat lung fibroblasts by up-regulating the PDGF-Rα. These data suggest that IL-13 and IL-1β contribute to the progression of airway fibrosis during the pathogenesis of asthma through a PDGF-AA/PDGF-Rα autocrine loop.
MATERIALS AND METHODS

Reagents
Recombinant human interleukin-13, anti-human PDGF-AA neutralizing antibody, and anti-STAT-1 antibody were obtained from R&D Systems, Inc. (Minneapolis, MN). STAT-6 and phospho-STAT-6 antibodies were purchased from Cell Signaling Technologies (Beverly, MA). Anti-human PDGF-Rα and anti-human PDGF-Rβ antibodies were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Recombinant murine IL-1β, recombinant human PDGF-AA, and recombinant human PDGF-BB were purchased from Upstate Biotechnologies (Lake Placid, NY). 125 
I-PDGF-AA was obtained from Biomedical Technologies (Stoughton, MA). [methyl-
3 H]thymidine was purchased from Amersham Pharmacia Biotech (Piscataway, NJ).
Cell culture
Primary passage rat pulmonary fibroblasts were isolated from male Sprague-Dawley rats as described previously (15) . Primary passage murine pulmonary fibroblasts were isolated from STAT-6 −/− , balb/c, and C57 mice that had been purchased from The Jackson Laboratory (Bar Harbor, ME). Primary passage murine pulmonary fibroblasts were isolated from TGF-α 3 H]thymidine incorporation was measured by diluting 100 µl solubilized cells in 1 ml EcoLume liquid scintillation cocktail (ICN Biomedicals, Costa Mesa, CA) and counting for 2 min per sample using a Beckman LS 6500 scintillation counter.
Preparation of cell lysates
Cultures of fibroblasts were grown to confluence in 100 mm dishes and growth arrested in SFDM for 24 h. Cell lysates were collected by washing the cells once with phosphate-buffered saline (PBS) on ice, and 200 µl of lysis buffer (50 mM Tris-HCl pH 7.4, 1% Triton X-100, 150 mM NaCl, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 0.25% sodium deoxycholate, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 mM sodium vanadate, and 1 mM sodium fluoride) were added to the cells. The cells were scraped from the dish in the lysis buffer. The lysed cells were sonicated for 1 min and spun in a microfuge at maximum speed for 5 min to fractionate insoluble DNA and chromatin proteins from the soluble cellular proteins in the lysis.
Western blot analysis
Samples were separated by SDS-PAGE, transferred to nitrocellulose membrane, and blocked for 1 h in 5% nonfat milk in Tris-buffered saline (TBS -20 mM Tris, 137 mM NaCl, and 0.1% Tween-20). The blot was then incubated at 4°C overnight in a 1:1000 dilution of primary antibody followed by incubation for 1.5 h in a 1:2000 dilution of horseradish peroxidase (HRP)-conjugated secondary antibody. The immunoblot signal was detected and visualized through enhanced chemiluminescence. The blot was then stripped of antibody and signal by incubating the membrane in stripping buffer (62.5 mM Tris pH 6.7, 2% SDS, 100 mM β-mercaptoethanol) for 30 min at 50°C. The blot could then be reprobed using a different primary antibody in the same procedure described above.
Preparation of IL-13-conditioned media
Fibroblast cultures were grown to confluence and treated with increasing doses of IL-13 or SFDM as a control for 1 h. The cells were washed once and then incubated in fresh SFDM for 3 h. The conditioned media were collected and used for cell proliferation assays or then concentrated 100x by lyophilizing the media and resuspending the dried pellet in water. The conditioned media proteins were separated by PAGE under nonreducing conditions and analyzed using a polyclonal antibody raised against human PDGF-AA (R&D Systems).
Gel filtration chromatography
Rat lung fibroblasts were grown to confluence in 175-cm 2 flasks and treated with SFDM alone or containing 100 ng/ml IL-13 for 4 h. The cells were then washed once, and fresh SFDM was incubated with the cells for 24 h. Conditioned media were collected and concentrated 30-fold with an Amicon 43mm YM5 Membrane (Amicon, Danvers, MA). This 30x-conditioned medium, 500 µl, was passed through a Superose 12 FPLC gel filtration column (Pharmacia) equilibrated with PBS (pH 7.5) operating at a flow rate of 0.5 ml/min. The fractions were diluted 1:1 with SFDM and 0.2 µM filtered for subsequent analysis in [ 3 H]thymidine incorporation assay.
I-PDGF-AA binding assay
Rat lung fibroblasts in 24-well plates were grown to confluence in 10% FBS/DMEM and then rendered quiescent for 24 h in SFDM. Cells were then treated with an agent of interest for 24 h. Cultures were chilled to 4°C, rinsed in cold binding buffer (Ham's F-12 with HEPES, CaCl 2 , and 0.25% bovine serum albumin), and exposed to 2 ng/ml 125 I-PDGF-AA for 3-4 h at 4°C on an oscillating platform in the absence or presence of 500 ng/ml nonradioactive PDGF-AA to measure total and nonspecific binding, respectively. Cells were then rinsed three times in icecold binding buffer, solubilized in 1% Triton X-100, 0.1% bovine serum albumin, and 0.1 M NaOH, and cell-associated radioactivity was measured with a γ-counter. Specific binding was defined as the difference between total and nonspecific binding.
Statistical analysis
Statistical analysis was performed by ANOVA and two-sample t tests. A P value of <0.05 was considered to be significant.
RESULTS
IL-13-induced secretion of a soluble mitogen
IL-13 caused a concentration-dependent increase in rat lung fibroblast mitogenesis that was greater at 48 h posttreatment as compared with 24 h posttreatment ( Fig. 1) . In contrast, PDGF-BB induced a maximal mitogenic response 24 h posttreatment. The delayed kinetics of IL-13-induced mitogenesis prompted us to investigate if secondary mediators were involved in the mechanism by which IL-13 induced cell proliferation. Confluent, quiescent cultures of rat lung fibroblasts were treated with IL-13 (100 ng/ml) for 1 h, then washed to remove residual IL-13, and incubated in fresh media. The conditioned medium was collected at various time points and assayed for mitogenic activity on fresh cultures of rat lung fibroblasts in the presence of [ 3 H]thymidine for 24 h. Conditioned medium collected 1-6 h after IL-13 treatment maximally stimulated mitogenesis in the 24 h [ 3 H]thymdine assay (Fig. 2 ). These data indicated that a soluble mitogen was secreted by the lung fibroblasts after IL-13 treatment. Moreover, because a 24 h incubation period is required for maximal [ 3 H]thymidine uptake into DNA with directly added exogenous growth factor, this additional 1-6 h window wherein a secondary soluble mitogen was produced in response to IL-13 explained why we observed a greater mitogenic response to IL-13 at 48 h vs. 24 h (Fig. 1 ).
IL-13 has been reported to stimulate the mitogenesis of normal human bronchial epithelial cells by causing the release of membrane-tethered transforming growth factor-α (TGF-α; ref 18) . Furthermore, mice deficient in TGF-α are protected from bleomycin-induced lung fibrosis and collagen accumulation (16) . Therefore, we first hypothesized that TGF-α could be the soluble mitogen involved in IL-13-induced proliferation of lung fibroblasts. However, treatment of fibroblasts isolated from the lungs of TGF-α deficient mice with IL-13 resulted in dosedependent proliferation of the cells comparable to the IL-13-stimulated mitogenic activity seen in wild-type cells (data not shown). Therefore, we concluded that TGF-α was not mediating the IL-13-stimulated mitogenesis of lung fibroblasts.
Identification of the IL-13-induced soluble mitogen as PDGF-AA
A recent study by Lee et al. (19) used microarray analysis to determine the gene expression profile in human lung fibroblasts in response to treatment with IL-13. This investigation showed that mRNA corresponding to PDGF-AA was one of several genes coding for soluble growth factors up-regulated in the fibroblasts upon exposure to IL-13. Of these soluble growth factors, PDGF-AA is the only one with an approximate molecular mass of 30 kDa. Therefore, we investigated the hypothesis that PDGF-AA was the soluble factor involved in mediating mitogenesis of lung fibroblasts in response to IL-13. To determine whether or not the soluble mitogen present in conditioned media from IL-13 treated fibroblasts was PDGF-AA, we fractionated the conditioned medium using size exclusion, gel filtration chromatography. The resulting fractions were then applied to fresh cultures of rat lung fibroblasts, and proliferation was assessed using [ 3 H]thymidine uptake assay. The data show that the fraction containing the majority of the mitogenic activity eluted with an apparent molecular mass of ~30 kDa (Fig. 3A) . Moreover, we assayed the column fractions of IL-13-stimulated human lung fibroblast conditioned medium for PDGF-AA immunoreactivity by Western blot (Fig. 3B) . Fibroblast PDGF-AA coeluted with the major peak of mitogenic activity. Coincubation of human lung fibroblasts with increasing concentration of an anti-PDGF-AA neutralizing antibody resulted in a dose-dependent inhibition of IL-13-induced and PDGF-AA-induced mitogenesis but did not affect PDGF-BB-induced mitogenesis (Fig. 4A ). In addition, Western blot analysis showed that IL-13 caused a strong, concentration-dependent increase in PDGF-AA protein levels in the CM from human lung fibroblasts (Fig. 4B ).
IL-13 does not stimulate the proliferation of Patch embryonic fibroblasts lacking the PDGF-Rα
To further characterize the mechanism by which PDGF-AA mediates IL-13-stimulated mitogenesis of lung fibroblasts, we used cultures of embryonic fibroblasts isolated from mice carrying the Patch mutation (20) . These mice lack the gene encoding PDGF-Rα, to which PDGF-AA binds and initiates signaling for cell growth. Cultures of murine wild-type embryonic fibroblasts (3T3 D1), Patch mutant embryonic fibroblasts (PhB; ref 17) , as well as a transgenically modified PhB that had been transfected with a human PDGF-Rα gene using a retroviral expression vector (Ph21A-7; ref 17) , were grown to confluence and analyzed for IL-13-stimulated mitogenesis. Immunoblot analysis verified the absence of PDGF-Rα protein expression in the PhB cells, while expression of the receptor was high in wild-type and Ph21A-7 fibroblasts (Fig. 5A) . The expression of PDGF-Rβ, the gene for which is not deleted as a result of the Patch mutation, was detected in all three fibroblast lysates. Both IL-13 and PDGF-AA failed to stimulate mitogenesis in the PhB fibroblast cultures, whereas PhB fibroblast growth increased over fivefold in response to treatment with PDGF-BB, an isoform of PDGF that binds to the PDGF-Rβ (Fig. 5B) . In contrast, all three mitogens stimulated cell proliferation in wild-type (3T3 D1) fibroblast cultures. Similarly, the Ph21A-7 fibroblast cultures proliferated upon stimulation with IL-13 and PDGF-AA, as well as PDGF-BB. These results indicated that the transgenic expression of a PDGF-Rα gene in the PhB strain enabled the fibroblasts to respond to PDGF-AA and IL-13. Furthermore, these data demonstrated that PDGF-Rα is required for IL-13-stimulated mitogenesis of lung fibroblasts and provided further evidence that PDGF-AA mediates the mitogenic effects of IL-13. To ensure that the lack of IL-13-stimulated mitogenic activity in PhB cells was not due to impaired STAT-6 signaling as a result of the Patch mutation, we performed Western blotting using phospho-STAT-6 and total STAT-6 antibodies. This experiment demonstrated that STAT-6 was phosphorylated in response to IL-13 treatment in PhB, PhA21-7, and 3T3-D1 cells (Fig. 5C ).
IL-13-stimulated fibroblast proliferation and PDGF-AA secretion is STAT-6 dependent
IL-13 exerts many of its effects through STAT-6, and STAT-6-deficient (STAT-6 −/− ) mice have proven to be a very useful tool in establishing requirements for STAT-6 in mediating T cell functions, particularly those directed by IL-13 and IL-4 (21, 22) . Analysis of STAT-6-deficient mice has revealed that they are protected from allergen-induced airway inflammation and hyperresponsiveness (10, 11) , and this protection results from a disruption of IL-13 and IL-4 signaling. To determine if IL-13-stimulated mitogenesis was dependent on STAT-6 signaling, we isolated lung fibroblasts from STAT-6-deficient mice and wild-type balb/c mice with an intact STAT-6 gene. The absence of STAT-6 protein was verified by Western blot analysis (Fig.  6A ). IL-13 induced mitogenesis in wild-type balb/c lung fibroblasts but did not stimulate mitogenesis in lung fibroblasts isolated from STAT-6 −/− mice (Fig. 6B) . In contrast, the STAT-6 −/− cells responded to PDGF-AA and PDGF-BB stimulation with a similar increase in
]thymidine uptake as that of wild-type cells. Therefore, these data demonstrate that signaling through STAT-6 is required for IL-13-induced fibroblast proliferation, but PDGF-AA does not require STAT-6. To determine if the soluble mitogenic activity present in conditioned media from IL-13-treated lung fibroblasts was STAT-6 independent, we performed an experiment in which conditioned media from IL-13-stimulated balb/c wild-type fibroblasts were assayed for mitogenic activity on STAT-6 −/− fibroblasts (Fig. 6C) . The conditioned media from the balb/c wild-type fibroblasts stimulated the mitogenesis of STAT-6 −/− fibroblasts, demonstrating that the soluble mitogen present in the IL-13-stimulated conditioned media acted independently of STAT-6. This observation was consistent with our previous findings that the IL-13-stimulated soluble mitogen is PDGF-AA.
IL-1β synergistically enhances IL-13-induced mitogenesis by up-regulation of the PDGF-Rα
Interleukin-1β is a cytokine derived from alveolar macrophages that has been reported to stimulate mitogenesis via a PDGF-AA autocrine loop (23) . Moreover, our previous work has shown that IL-1β up-regulates expression of the PDGF-Rα on rat lung fibroblasts (24) (25) (26) (27) . We hypothesized that IL-13 could stimulate fibroblast mitogenesis through a mechanism similar to that of IL-1β. Western blot analysis clearly showed that IL-1β, but not IL-13, up-regulated the PDGF-Rα (Fig. 7A) . Neither cytokine altered expression of the PDGF-Rβ. We also performed [ 125 I]PDGF-AA binding assays using rat lung fibroblasts that were pretreated with IL-13 or IL-1β. The data clearly show that IL-13 did not up-regulate PDGF-Rα, whereas IL-1β was a potent inducer of PDGF-Rα expression (Fig. 7B ). Based on our observations that IL-13 stimulates production of PDGF-AA and that IL-1β up-regulates PDGF-Rα, we next investigated possible synergy between IL-13 and IL-1β in promoting growth. Rat lung fibroblasts were pretreated with IL-1β for 24 h to up-regulate the expression of PDGF-Rα and then treated with increasing concentrations of IL-13 and assayed for mitogenesis. Treatment of rat lung fibroblasts with 10 ng/ml IL-1β alone had a minimal effect on mitogenesis (1.20±0.15 fold increase over serum-free media alone). IL-13 alone caused an ~2.5 fold increase in mitogenesis. However, the combination of IL-1β pretreatment followed by IL-13 treatment caused an ~8-fold increase in mitogenesis (Fig. 7C ). These data demonstrated that IL-13 and IL-1β act synergistically to promote mitogenesis and do so coordinately by up-regulating PDGF-AA and the PDGF-Rα, respectively.
DISCUSSION
The development of peribronchiolar fibrosis is a major feature of airway remodeling in asthma. Although IL-13 has been established as a critical mediator of airway fibrosis, the mechanisms through which IL-13 causes fibroblast proliferation have not been elucidated. In the current study, we show that IL-13 stimulates fibroblast proliferation through STAT-6-dependent secretion of PDGF-AA. Moreover, the mitogenic effect of IL-13 was synergistically enhanced by IL-1β, which up-regulates the cell-surface PDGF-Rα to which PDGF-AA selectively binds (24) (25) (26) (27) . Collectively, our findings provide evidence for a PDGF-AA autocrine loop initiated by the cooperative actions of IL-13 and IL-1β.
Several lines of evidence show PDGF-AA as the soluble mitogen released by IL-13-treated lung fibroblasts. First, we demonstrated that a soluble mitogen with an apparent molecular mass of ~30 kDa was present in conditioned media from IL-13-treated human lung fibroblasts that coeluted with immunoreactive fibroblast PDGF-AA. PDGF-AA is a protein of ~30 kDa that is a known mitogen for fibroblasts and other cells of mesenchymal origin (28, 29) . Furthermore, Lee et al. (19) used micoarray technology to show that IL-13 stimulated the expression of several genes encoding soluble peptides by human lung fibroblasts, yet PDGF-AA was the only factor of ~30 kDa that possesses mitogenic activity for fibroblasts. Nevertheless, PDGF-AA was not established as mediating IL-13-induced growth in that study. We showed by Western blot analysis that PDGF-AA protein was released into the media by human lung fibroblasts in response to IL-13. In addition, treatment of human lung fibroblasts with a neutralizing antibody specific to PDGF-AA resulted in a dose-dependent attenuation of IL-13-stimulated fibroblast proliferation. Finally, we demonstrated that the PDGF-Rα is required for IL-13-stimulated mitogenesis of lung fibroblasts since embryonic fibroblasts isolated from mice lacking the PDGF-Rα gene (Patch mutation) did not proliferate in response to IL-13 or PDGF-AA, whereas IL-13 did stimulate mitogenesis of fibroblasts from mutant mice in which human PDGF-Rα is transgenically expressed. Moreover, we showed that IL-13 induced STAT-6 signaling was not impaired as a result of the Patch mutation. Taken together, these data strongly support a role for PDGF-AA and its receptor, PDGF-Rα, as an autocrine signaling loop in IL-13-stimulated fibroblast growth.
Lung fibroblasts express both chains of the type 2 IL-4 receptor, IL-4 receptor α (IL-4Rα), and IL-13 receptor α 1 (IL-13Rα1; ref 30) , which are required to initiate cell signaling in response to IL-13. Many of the biological responses to IL-4 and IL-13 are mediated through STAT-6 (10, 12). Therefore, it was not surprising that IL-13-stimulated lung fibroblast mitogenesis did not occur in fibroblasts isolated from the lungs of STAT-6 −/− mice. However, the mitogenic effect elicited by the soluble mediator that we identified as PDGF-AA was demonstrated to occur independently of STAT-6, as conditioned media from IL-13-stimulated wild-type balb/c fibroblasts induced proliferation of STAT-6 −/− fibroblasts. Therefore, we conclude that STAT-6
is required for the IL-13-stimulated production of PDGF-AA, yet PDGF-AA-induced mitogenesis is STAT-6 independent. We propose a model showing that IL-13 acts through STAT-6 to cause secretion of PDGF-AA, which subsequently stimulates mitogenesis of lung fibroblasts via activation of the PDGF-Rα (Fig. 8) .
Much evidence implicates a role for cytokine stimulation of PDGF-AA autocrine secretion to induce fibroblast proliferation. Raines et al. (23) first demonstrated that the mitogenic activity resulting from stimulation by IL-1β on cultured fibroblasts and smooth muscle cells could be attributed to PDGF-AA. We have shown previously that IL-1β is a potent up-regulator of the PDGF-Rα (24−27). Battegay et al. (31) showed that low concentrations of TGF-β, typically a growth inhibitor, could stimulate fibroblast, smooth muscle cell, and chondrocyte proliferation via PDGF-AA autocrine secretion. These results were corroborated by Win et al. (32) who showed that human liver fibroblasts responded to TGF-β1 by producing PDGF-AA and that the mitogenic effect of TGF-β1 on the cells could be blocked with PDGF-AA specific antibodies. However, relatively high concentrations of TGF-β1 suppress fibroblast growth by downregulating the PDGF-Rα (31, 33) . TNF-α also stimulates a PDGF-AA autocrine loop in cultured human fibroblasts (34) . However, TNF-α does not alter the expression of PDGF-Rα (26) . We showed that IL-13, like TNF-α, stimulated PDGF-AA release but alone did not alter the expression of the PDGF-Rα in rat lung fibroblasts.
The mitogenic effect of IL-13 on rat lung fibroblasts was enhanced after pretreatment of the cultures with IL-1β. We previously reported that IL-1β enhances PDGF-stimulated mitogenesis of rat lung fibroblasts via p38 MAP kinase-regulated stabilization of PDGF-Rα mRNA, which results in increased cell-surface PDGF-Rα (27) . We found that IL-13 did not up-regulate PDGF-Rα. However, we postulated that IL-13-stimulated release of PDGF-AA could be augmented by treatment with IL-1β. Indeed, we observed that IL-1β synergistically enhanced the mitogenic effect of IL-13. Synergistic interactions of IL-13 and IL-1β have been previously reported to result in increased eotaxin release and decreased RANTES production in human airway smooth muscle cells (35) . Similarly, IL-13 was reported to enhance the stimulatory effect of IL-1β on induction of IL-1 receptor antagonist in human hepatoma HepG2 cells (36) . Both IL-13 and IL-1β are detectable in elevated concentrations during the progression of allergic asthma (2, 37) . Activated macrophages that produce IL-1β and T-helper lymphocytes that secrete IL-13 are both involved in the proinflammatory response following allergen challenge (2, 4, 24, 27) . Thus, the simultaneous presence of these cytokines in the tissue surrounding the airways may contribute to the synergistic mediation of fibroblast proliferation, a key feature that contributes to the progression of airway fibrosis.
The role of IL-13 in eliciting myofibroblast proliferation in vitro has clear clinical relevance to the progression of airway fibrosis in asthma. We have shown that the mitogenic effect of IL-13 occurs to a similar magnitude in rat, mouse and normal human lung fibroblasts in culture. Taken together, these data suggest a similar mechanism involving IL-13-induced PDGF-AA secretion in all of these cell types. Kraft et al. (14) have shown that IL-13 stimulates proliferation of airway fibroblasts in cultures that were isolated from patients with mild asthma. Furthermore, they demonstrated that dexamethasone, a corticosteroid known to upregulate PDGF-Rα (38) , augmented the effect of IL-13 on fibroblast proliferation in mild asthma (14) . These observations appear to parallel our evidence of the in vitro effects of IL-13, the release of PDGF-AA, and apparent synergy between IL-13 and IL-1β on cell proliferation. Therefore, our study provides evidence for a mechanism that may explain the observed effects of IL-13 on cell proliferation in asthma and implicates PDGF-AA and its receptor, PDGF-Rα, as a potential therapeutic target for the treatment of airway fibrosis in asthma. Specifically, there is evidence in animal models showing that pharmacologic agents that inhibit tyrosine phosphorylation within the intracellular domain of PDGF receptors reduce fibrosis by limiting myofibroblast replication and thereby reducing the major cell type that deposits collagen (39) . PDGF receptor tyrosine kinase inhibitors could hold promise for the treatment of airway fibrosis in chronic asthma.
In conclusion, we have shown that IL-13 stimulates mitogenesis of lung fibroblasts and that this effect is dependent on STAT-6 signaling. Furthermore, we provide evidence that IL-13 induces the release of PDGF-AA as a soluble mediator for stimulating cell proliferation. The mitogenic effect IL-13 can be augmented by pretreatment of the fibroblasts with IL-1β, which up-regulates PDGF-Rα expression and allows for the establishment of an IL-13-stimulated PDGF-AA autocrine loop. These data suggest a mechanism by which IL-13 contributes to the pathogenesis of airway fibrosis through interactions with other proinflammatory cytokines. of PDGF receptors using whole cell lysates of embryonic fibroblast cultures from PDGF-Rα-deficient Patch mouse strain (PhB), wild-type strain (3T3 D1) possessing PDGF-Rα, and a transgenically modified Patch strain (Ph21A-7) (19) . The Ph21A-7 strain had been transfected with the human PDGF-Rα gene using a retroviral expression vector (19) . B) [ 3 H]thymidine uptake assay showing mitogenic responses of 3T3 D1 ( ), PhB ( ), or Ph21A-7 (▲) embryonic fibroblasts to IL-13, PDGF-AA or PDGF-BB. Data are expressed as the mean fold-increase above control (SFDM) of quadruplicate wells from a single experiment typical of 3. Bars denote the SE. C) Western blot showing phosphorylation of STAT-6 (p-STAT-6) and total STAT-6 protein in 3T3-D1, PhB, and PhA21-7. These data demonstrate STAT-6 signaling is intact in PhB and PhA21-7 cells with deleted PDGF-Rα. Rα. IL-13 stimulates the release of PDGF-AA from lung fibroblasts, which binds the PDGF-Rα and activates a MAPKdependent signaling pathway that culminates in a mitogenic response. IL-13-induced release of PDGF-AA is STAT-6-dependent, as STAT-6 null fibroblasts do not proliferate in the presence of direct IL-13 treatment. However, STAT-6−/− lung fibroblasts undergo mitogenesis in the presence of conditioned medium from Balb/c cells treated with IL-13, indicating that PDGF-AA acts via a STAT-6-independent mechanism. Furthermore, IL-1β and IL-13 act synergistically to induce mitogenesis. IL-1β up-regulates the PDGF-Rα through a p38-dependent mechanism, resulting in an enhanced mitogenic response to PDGF-AA.
